Researchers identify protein which could help protect against neuro-degenerative conditionsMay 30, 2003A team of researchers from Imperial College London, the Charing Cross Hospital and University College London have identified a protein which could be used to protect against neuro-degenerative conditions such as Alzheimer’s, Parkinson’s, Huntington’s, motor neurone diseases and the damage caused by strokes. According to research published today in The Journal of Biological Chemistry, the researchers discovered that the naturally occurring protein, 27-kDa heat shock protein (HSP27) was able to reduce cell death in the brain. Professor Jacqueline de Belleroche, senior author on the paper, from Imperial College London and the Charing Cross Hospital, comments: “At present, there is no cure for neuro-degenerative diseases, such as Alzheimer’s and Parkinson’s, but the discovery of the beneficial effects of this protein in the brain may provide us with a way to at least slow down the disease process.” For the experiment, the researchers used transgenic mice, which had high levels of HSP27 throughout the brain, spinal cord and other tissues. This was found to reduce mortality rate and neuronal cell death in the hippocampus, a part of the brain affected by neurological diseases. Similar results were also obtained when HSP27 was injected directly into the brain. Professor de Belleroche adds: “Although this is unlikely to provide a cure for neuro-degenerative disorders, it could be vital in slowing their progress. Eventually it may be possible to use a drug to increase levels of HSP27 in the brain which could be given to those suffering from neuro-degenerative diseases.” Heat shock proteins (HSPs) are a group of proteins present in all cells in all life forms, and are induced when a cell undergoes environmental stresses such as heat, cold and oxygen deprivation. Imperial College, University of London |
|||||||||||||||||||||
| Related Alzheimer Disease Current Events and Alzheimer Disease News Articles Delirium in hospitalized adults: Situation critical, no relief available Every year as many as seven million adults in the United States experience delirium during hospitalization. New data demonstrate potential for early detection of Alzheimer's disease Data published in the June issue of the Journal of Alzheimer's Disease demonstrated that minimally-invasive biospectroscopy was able to identify changes in oxidative stress (OS) levels in blood plasma, which may prove to be a useful biomarker in the early detection of Alzheimer's disease. Another McGill/JGH breakthrough opens door to early Alzheimer's diagnosis A new diagnostic technique which may greatly simplify the detection of Alzheimer's disease has been discovered by researchers at McGill University and the affiliated Lady Davis Institute for Medical Research at Montreal's Jewish General Hospital (JGH). Measuring brain atrophy in patients with mild cognitive impairment Scientists at the University of California, San Diego School of Medicine have shown that a fully automated procedure called Volumetric MRI - which measures the "memory centers" of the brain and compares them to expected size - is effective in predicting the progression from mild cognitive impairment (MCI) to Alzheimer's disease. Commonly used medications may produce cognitive impairment in older adults Many drugs commonly prescribed to older adults for a variety of common medical conditions including allergies, hypertension, asthma, and cardiovascular disease appear to negatively affect the aging brain causing immediate but possibly reversible cognitive impairment, including delirium, in older adults. Commonly used ulcer drugs may offer treatment potential in Alzheimer's disease In a new study, published in the May issue of Elsevier's Experimental Neurology, scientists at the University of British Columbia have discovered that drugs commonly used to treat ulcers have significant neuroprotective properties, which appear to be enhanced when used in combination with ibuprofen, a widely used anti-inflammatory drug. New test for mysterious metabolic diseases developed at Stanford/Packard Scientists at Stanford University School of Medicine have devised a much-needed way to monitor and find treatments for a mysterious and devastating group of metabolic diseases that arise from mutations in cells' fuel-burning mechanism. Recalibrating 'fight or flight' A Canadian/U.S. research team has reported a novel approach to stimulating recovery from chronic stress disorders. Details of the therapeutic model, which exploits the natural dynamics of the body's "fight or flight" system, are published January 23 in the open-access journal PLoS Computational Biology Vitamin B does not slow cognitive decline in Alzheimer's A clinical trial led by Paul S. Aisen, M.D., professor of neurosciences at the University of California, San Diego School of Medicine, showed that high-dose vitamin B supplements did not slow the rate of cognitive decline in patients with mild to moderate Alzheimer disease. Protecting patient privacy the new fashioned way Protecting patient privacy has been recognized as the duty of health-care providers for about as long as doctors have seen patients. In 1996 that duty became a legal obligation when Congress passed the Health Insurance Portability and Accountability Act. More Alzheimer Disease Current Events and Alzheimer Disease News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||